Clinical Trials Logo

Encephalitis, Japanese clinical trials

View clinical trials related to Encephalitis, Japanese.

Filter by:

NCT ID: NCT00981175 Completed - Clinical trials for Japanese Encephalitis

A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults

Start date: April 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, immunogenicity, and duration of immunity of one or two doses of ChimeriVax™-JE vaccine separated by 5 or 6 months in adults. Objectives: Safety: - Obtain safety and tolerability data of a single, fixed dose of ChimeriVax™-JE compared with a placebo in adult volunteers (≥ 18 to <55 years) without prior Japanese encephalitis (JE) vaccination. Immunogenicity: - Obtain data on the antibody response in adult volunteers following administration of ChimeriVax™-JE - Assess the durability of the immune response in adult volunteers over 60 months following one or two doses of ChimeriVax™-JE.

NCT ID: NCT00938379 Recruiting - Malaria Clinical Trials

Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR

Start date: July 2009
Phase: Phase 3
Study type: Interventional

Rural communities involved in agriculture are often at highest risk of insect-borne diseases in Southeast (SE) Asia. Skin-applied insect repellents may prove a useful means of reducing mosquito-borne diseases for those people working outdoors in high risk areas. This trial is evaluating the use of insect repellent (20% diethyltoluamide) to reduce incidence of malaria, Japanese Encephalitis and Dengue. The investigators will recruit up to 1000 households from 100 villages in rural Laos. In each house the investigators shall recruit up to 5 individuals. Half of households will be randomised to repellent, half to a placebo. All individuals will be provided with insecticide treated bed nets for use at night. All household occupants will be followed for 7 months to record malaria cases by Rapid Diagnostic Test every month. Blood spots will be collected at start and end of study to measure Japanese Encephalitis and Dengue. All positive cases will be promptly treated. Outcome will be reduction in number of malaria cases (primary outcome) and Dengue/Japanese Encephalitis (secondary outcomes).

NCT ID: NCT00776230 Completed - Clinical trials for Japanese Encephalitis

Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling

Start date: September 2008
Phase: Phase 3
Study type: Interventional

The objective is to assess immunogenicity of a commercial IC51 batch at 3 different time points post filling (12, 18, 24 months) in terms of Geometric Mean Titers (GMT) for anti-JEV neutralizing antibodies at Day 56 after the first vaccination.

NCT ID: NCT00735644 Completed - Hepatitis A Clinical Trials

Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines

Start date: August 2008
Phase: Phase 3
Study type: Interventional

This study is to assess the safety and immunogenicity of three consecutive lots of JE-CV in toddlers aged 12-18 months. Primary objective: To demonstrate the bio-equivalence of three lots of JE-CV vaccine manufactured by sanofi pasteur. Secondary objective: To describe the safety of vaccination in all subjects

NCT ID: NCT00694460 Completed - Rabies Clinical Trials

Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers

Start date: August 2002
Phase: Phase 2
Study type: Interventional

This study evaluated the safety and immunogenicity of rabies vaccine and Japanese encephalitis vaccine in toddlers. All children developed adequate immune responses. Rabies vaccination with PCECV did not interfere with the antibody response to Japanese encephalitis vaccine. The rabies vaccine PCECV and Japanese encephalitis vaccine are safe and immunogenic when administered concomitantly to toddlers.

NCT ID: NCT00621764 Completed - Hepatitis A Clinical Trials

Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children

Start date: March 2008
Phase: Phase 2
Study type: Interventional

Safety: To describe the safety profiles following vaccination. Immunogenicity: To describe the immune response after a single dose of vaccine.

NCT ID: NCT00605085 Completed - Clinical trials for Japanese Encephalitis

Safety and Tolerability of the Japanese Encephalitis Vaccine IC51

Start date: October 2005
Phase: Phase 3
Study type: Interventional

The objective is to investigate the safety and tolerability of Japanese Encephalitis vaccine IC51 with an inactive control in healthy subjects aged > or = 18 years

NCT ID: NCT00604708 Completed - Clinical trials for Japanese Encephalitis

Immunogenicity Study of the Japanese Encephalitis Vaccine IC51

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The objective is to demonstrate the non-inferiority of the Japanese Encephalitis vaccine IC51 compared to JE-VAX in healthy subjects aged > or = 18 years

NCT ID: NCT00596271 Completed - Clinical trials for Japanese Encephalitis

Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Start date: September 2005
Phase: Phase 3
Study type: Interventional

The objective is to investigate the immunogenicity of the Japanese Encephalitis vaccine IC51 (JE-PIV) single and concomitant with HAVRIX® 1440

NCT ID: NCT00596102 Completed - Clinical trials for Japanese Encephalitis

Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51

Start date: October 2005
Phase: Phase 3
Study type: Observational

The study investigates the long term safety and immunogenicity of the Japanese Encephalitis vaccine IC51 up to month 60.